VMET Market Analysis

Fundamentals

Updated daily after market close
P/E ratio28.48Forward 32.47
EPS (TTM)$0.31573.0% YoY
Profit margin58.4%BASIC MATERIALS
Market cap$958.9MSmall cap

Valuation

Forward P/E
32.47
PEG ratio
P/B
2.62
P/S (TTM)
17.35
EV/EBITDA
14.13

Profitability & growth

ROE (TTM)
11.2%
Operating margin
90.6%
Revenue growth YoY
594.0%
Dividend yield
Beta
Last earnings
May 14, 2026 · Reported $0.28
Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

About Versamet Royalties Corporation Common Stock

Company profile

Viamet Pharmaceuticals Corp (VMET) is an innovative biopharmaceutical company dedicated to the development of advanced therapeutics targeting serious diseases, particularly in the areas of fungal infections and oncology, utilizing its proprietary metalloenzyme-based technology platform. With a robust and diversified clinical pipeline supported by strategic partnerships and a comprehensive intellectual property portfolio, Viamet is strategically positioned for significant growth. The company remains focused on addressing critical unmet medical needs and is committed to enhancing shareholder…

Classification

Exchange
NASDAQ
Country
USA
Currency
USD

Company profile

HQ
733 SEYMOUR STREET, VANCOUVER, BC
Fiscal year end
December
Latest quarter
Mar 31, 2026
Market cap$958.9M
Shares outstanding$108.6M
52W high$15.00
52W low$8.48

We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer